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Abstract
‘If anticoagulants had been administered sooner, my client would not have died’ was a central claim
put to us, as statistician expert witnesses, by a Claimant’s and Defendant’s lawyers. To assist other
litigants, and without identifying the speciﬁc case, we set out the study types that contribute to the
evidence base, and their limitations. We then explain why it is difﬁcult to adduce evidence about the
relative risk of dying from pulmonary embolism within 12 hours of admission to accident and
emergency even when it is well accepted that anticoagulation reduces the risk of dying within the
next seven days of patients at objectively conﬁrmed risk of pulmonary embolism. No matter how
much we may want an answer, or how tragic an individual outcome, we can only work from the
available evidence or work to improve the evidence base, which needs to be resourced.
Introduction
‘If anticoagulants had been administered sooner, my client
would not have died’ was a central claim put to us, as statis-
tician expert witnesses, by a Claimant’s and Defendant’s
lawyers.
One of us (JLH) has considerable experience of serving
as a statistician expert witness, mainly when life-expectancy
for individuals with cerebral palsy is at issue. In cerebral
palsy, rigorously analysed, well-collected registry data
1–3
provide common ground, which helps litigants to achieve
an expeditious and equitable resolution.
The other (SMB) has accepted instruction rarely, such
as when an anti-doping issue in sport turned on the design
of robust surveillance of cattle at slaughterhouses.
4 In that
instance, practical advice on being an expert witness was
sought from JLH and also obtained by reading the ﬁrst part
of the Royal Statistical Society’s guide.
5
The case in common was settled; and it was suggested
to SMB that lawyers might ﬁnd it helpful to have an acces-
sible account of the statistical issues therein. By that time,
SMB was aware that JLH had also prepared a report.
Without identifying the speciﬁc case, we set out why it
is particularly difﬁcult to acquire empirical evidence about
the risk of death from acute pulmonary embolism (PE)
within six or 12 hours of admission to Accident and
Emergency (A&E), with or without prescription of coagu-
lation. In part, the difﬁculty arises from a pharmaceutical
success so dramatic that further well-designed, epidemiolo-
gical research became prohibitively expensive.
Case history: in brief
Consider a patient who has undergone a hospital procedure
which is known to increase the risk of venous
thromboembolism (VTE). The patient has been advised to
be active at home, rather than sedentary; and, if he experi-
ences symptoms, to return immediately to A&E.
Some days later, the patient experienced shortness of
breath, called an ambulance, and was admitted to A&E.
Despite his medical history, differential diagnosis did not
include (the risk of) pulmonary embolism (PE), nor did an
episode of loss of consciousness promote PE above heart
failure as presumptive diagnosis. Anticoagulation was not
prescribed in the interim while another medical opinion
was awaited. The patient collapsed, and cardiac arrest
caused death, all within 12 hours of admission to A&E.
Autopsy conﬁrmed massive PE.
Contention
Had anticoagulation been prescribed in A&E prior to the
patient’s collapse, then – on the balance of probabilities –
the patient’s death from acute PE within 12 hours of admis-
sion to A&E would have been averted. We were separately
instructed by the opposing sides to evaluate the evidence
for this contention.
Challenge
The question asked of one of us was: ‘How long is it
before injection with heparin prevents death from PE?
Subcutaneous injection with low-molecular-weight heparin
(LMWH) is absorbed within 30–60 minutes of injection.’
Clinicians, statisticians and lawyers will promptly think of
ways in which the question should be reﬁned. Email: sheila.bird@mrc-bsu.cam.ac.uk
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Should the patient’s age and sex be taken into account? Is
the disease which the hospital procedure was intended to
treat relevant? Are there other aspects of the patient’s health
or hospital care which are important? These are serious
considerations, and natural ones when considering a par-
ticular person. However, we show below that it is difﬁcult
to answer even the simple question: ‘How long does it take
for subcutaneous injection of LMWH to prevent death
from PE?’
Almost always, a statistician expert witness will wish to
clarify or reﬁne the questions she is asked. The contention
and the question above are subtly different. The contention
includes assumptions about the decision to prescribe antic-
oagulation, and the timing of both the decision and the
administration of anticoagulant treatment. The question is
simpler. If the question cannot be answered, then the
further issues of delay in diagnosis and of prescription or
administration may be hardly worth pursuing.
Schematic
Below is a schematic for the progression of venous
thromboembolism (VTE) through ﬁve stages.
1. Venous thromboembolism (VTE);
2. Symptomatic VTE;
3. Pulmonary embolism (PE);
4. Symptomatic non-massive PE;
5. Symptomatic massive PE.
Not all ﬁve stages need be experienced by every patient.
Not all patients survive to be admitted to hospital. The
patient’s PE risk may, or may not, be recognized.
Anticoagulation, either before or after conﬁrmed PE diag-
nosis, may reduce the risk of non-fatal PE recurrence or PE
death.
From any stage in the evolution of VTE, a patient may:
(a) Be admitted to A&E;
(b) Experience sudden PE death (with or without A&E
admission);
(c) Experience non-PE death (with or without A&E
admission).
Non-PE death includes death from cerebral haemorrhage,
which can itself arise from the administration of anticoagu-
lants. Morbidities which do not lead to death are also poss-
ible in relation to anticoagulation.
Statistical issue
Highly time-speciﬁc hazard rates have to be compared, that
is: the risks of death in speciﬁed short intervals, such as 2–4
hours after admission or administration. For this comparison,
the start time is properly A&E admission. The relevant risk
set is patients (with different co-factors) who were admitted
to A&E and for whom discharge diagnosis includes PE, and
who were (or were not) administered anticoagulation, such
as subcutaneous injection of LMWH, at some elapsed time
after admission to A&E.
To answer the question, data are required on the time
of injection of heparin for a relevant group of patients, and
the time and cause of death, or the time when the patient
was last known to be alive, which is often the time of
hospital discharge.
To address the contention, data are required which
record several times for a well-deﬁned group of patients
who were admitted to A&E: the start time, which is A&E
admission still; the times of diagnosis, prescription and
injection of heparin or other anticoagulant; and time to
hospital discharge or death. Patients should all have been
admitted to A&E, and had a discharge diagnosis which
included PE. Additional information for each patient –
including age, sex, general health, medical care, and cause
of death for those who died – would be necessary.
Scientiﬁc literature
The Appendix (online-only) illustrates the types of evidence
available in the scientiﬁc literature, together with their
strengths and limitations for addressing the contention.
The types of evidence include randomized,
dose-ranging studies in young, healthy volunteers. In such
studies, the injection time for LMWH, the dose injected,
and appropriate blood levels at speciﬁed sampling times
thereafter are recorded. Blood level data are a surrogate for
when LMWH can be expected to begin to reduce the risk
of death from PE. Speciﬁcally, estimation focuses on how
blood levels evolve with time after administration of the
randomly assigned dose; and, for a given dose, how variable
the time course is between individuals. Translating results
from healthy volunteers to at-risk patients with
co-morbidities for whom the medication is ultimately
intended is at best indirect and so the next study type is a
trial in at-risk patients.
A randomized controlled trial (RCT) of a novel inter-
vention in at-risk patients, for whom diagnosis has been
objectively conﬁrmed, will occasionally provide such con-
vincing evidence of efﬁcacy that continued randomization
to the control group would be unethical. This was the case
in the late 1960s for intravenous heparin in PE-diagnosed
patients.
6 Later randomized studies focused on comparing
different forms of the intervention (such as intravenous
versus subcutaneous injection, or different LMWHs). As
the PE-fatality rate within seven days of randomization
would be expected to be low, surrogate outcomes – rather
than death or PE recurrence – might again be invoked
because of the large number of eligible patients required to
discern a modest differential impact on an already low
death rate.
A second tranche of the scientiﬁc literature concerns
non-randomized observational studies, which have the
advantage that they not only recruit many patients but also
reﬂect the range and reality of clinical practice. As in
RCTs, registries may insist on objective conﬁrmation of
diagnosis as an eligibility criterion but, unlike RCTs, regis-
tries do not have such a natural start time as the time of
randomization from which to begin their follow-up of
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hospital admission for their VTE diagnosis to have been
both suspected and conﬁrmed objectively.
We now illustrate the analytical consequences which
arise from (hypothetical) Registry R’s not having recorded
the exact times of: i) hospital admission, ii) objectively
conﬁrmed VTE diagnosis, and iii) VTE intervention,
let alone of iv) fatalities.
To be eligible for Registry R, patients had to have sur-
vived the elapsed time (of unknown duration) between i)
hospital admission and ii) objectively conﬁrmed VTE
diagnosis. The mean elapsed time may have been different
according to the intervention which R-registered patients
actually received, or according to their VTE progression at
hospital admission. In particular, for patients who received
LMWH, who were the majority, we do not even know
whether, on average: iii) time of administration of LMWH
preceded, or followed, ii) objectively conﬁrmed VTE
diagnosis. Nor do we know which zero-time [i), ii) or iii)]
marked the start of follow-up for R-registered patients who
received LMWH.
Table 1 shows a range of assumptions about how many
hours, on average, R-registered LMWH-treated patients
were actually at risk of PE fatality on Day 0 (hospital admis-
sion day) after having received LMWH. If we assume they
were at risk for 24 hours, then we obtain the biologically
improbable result that PE fatality rate on Day 0 was signiﬁ-
cantly lower than on Day 1. By assuming an average of 12
hours at risk on Day 0, we would estimate broadly equal
hazard rates on Day 0 and Day 1, whereas, if we assume
that, post-intervention, R-registered LMWH-treated
patients were at risk for an average of six hours only on Day
0, then we’d conclude that the hazard rate per 10,000
patient-days, in that six-hour period, was signiﬁcantly
greater than the time-speciﬁc risk on Day 1.
Table 1 shows a further reduction in PE fatality rate
after Day 7 for the Registry R’s LMWH-treated
VTE-conﬁrmed patients. Of course, patients’ PE fatality
risk may be decreasing over time for reasons of differential
frailty that are unconnected with the pharmaceutical inter-
vention they received.
In short, analysis of time-speciﬁc outcomes for
R-registered patients can only be conjectural because we do
not know from which zero-time patients’ follow-up has
been measured. In particular, inference about the mean dur-
ation of any LMWH refractory period (i.e. before
LMWH-associated PE fatality hazard reduction comes into
play) is conjectural – with or without allowance for VTE
progression at admission and for patients’ age, sex and
co-morbidity.
Discussion
Other study designs
The available studies do not contain sufﬁciently detailed
information to answer the question of how long it takes
‘before subcutaneous injection of LMWH reduces the risk
of death from PE’. The analysis of Registry R’s data, see
also Laporte et al.,
7 could, of course, have been improved
by detailed recording of times i) to iv). However, the case
at issue did not ﬁt the eligibility criteria for Registry R
anyway – because the patient’s death preceded objective
conﬁrmation of VTE diagnosis, which was at autopsy.
The best study design is one which marries the
record-linkage credentials of the ﬁnal study
8 in the
Appendix with abstraction of speciﬁc times (if indeed
recorded) from both A&E and other hospital notes; and
does so for tens of thousands of patients. Many patients
have to be included as fewer than four in 100 patients
admitted to A&E for whom discharge diagnosis includes
PE are expected to die within seven days of admission to
A&E; and LMWH treatment is very effective in patients
with objectively conﬁrmed VTE, of whom fewer than two
in 100 are expected to die within seven days from PE.
Times of interest would include biomarker levels measured
at protocol pre-speciﬁed times after the administration of
anticoagulation but would also have to include estimation
of the time interval in which PE occurred or re-occurred.
In a busy A&E department, the accurate recording of
times (to the minute or even hour) has to compete with
other activities, particularly in the case of seriously ill
Table 1 PE fatalities (with censoring of other-cause deaths) for (hypothetical) R-registered patients whose VTE diagnosis was objectively
conﬁrmed
Epoch Events Patient-days (pds)
Event rate
per 10,000 pds
Poisson 95% CI for event rate
per 10,000 pds
Low Molecular Weight Heparin (LMWH): 16202 patients
Day 0: 24 hrs 27 16202 16.7 11.0 to 24.2
Day 0: 12 hrs 27 8101 33.3 20.0 to 48.5
Day 0: 8 hrs 27 5400.7 50.0 32.9 to 72.7
Day 0: 6 hrs 27 4050.5 66.7 43.9 to 97.0
Day 1 50 16169.2 30.9 22.9 to 40.8
Day 1 þ Day 0: 12 hrs 77 24270.2 31.7 25.0 to 39.7
Day 2 þ 3 þ 4 105 48174.0 21.8 17.8 to 26.4
Day 5 þ 6 þ 7 88 46315.8 19.0 15.2 to 23.4
Day 8 þ 9 þ 10 36 43902.4 8.2 5.7 to 11.4
Day 11 þ 12 þ 13 12 43773.5 2.7 1.4 to 4.8
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ﬂuids. At the time of a death, concern for relatives may
well take precedence over making notes. If notes have to be
completed later, recall of times is unlikely to be accurate to
much less than ﬁfteen minutes: even that may be too opti-
mistic. The alternative of having additional staff, with a cle-
rical role
9 of noting exact times, would be intrusive for
patients, families and healthcare teams.
Such a study would also be prohibitively expensive.
Employing clerical staff to record precise times, and the
taking of additional, precisely timed biomarker measurements,
would also be for research purposes rather than routinely
required. Hence, the study would require both research
ethical approval and informed patient consent. There is a
good chance that patient or proxy consent would not be
given by a substantial proportion of patients, even with
substantial expenditure on gaining consent. For example,
consent was given for no more than half of all patients eligible
to be on a Canadian Stroke Register, and there were
major differences between those enrolled and those who
refused.
10,11
Costing an accurate record linkage and biomarker
study if the day-speciﬁc hazard is 1 to 5 deaths
per 1000 patients
Study size would need to be sufﬁcient at the lower day
hazard rate of one death per 1000 patients. Adequate esti-
mation of hazard rates for each 24-hour period for a speciﬁc
subgroup requires us to observe around 20 deaths for that
subgroup on any speciﬁc day. Taking demography and
co-morbidities into account could readily give rise to 10 sub-
groups, and hence the need to document 200,000 patients
who were admitted to A&E and whose discharge diagnosis
included PE. Allowing £75 for informed consent, biomarker
measurements and accurate recording would bring study costs
on 200,000 patients to around £15 million.
We can only conjecture at how much the public purse
has expended in the past ﬁve years on claims of clinical
negligence in respect of PE fatalities (see http://www.nhsla.
com/home.htm). However, if there were 20 such cases per
annum at an average cost of £750,000 each, then it would
take, for example, a 20% reduction in litigation costs over
the next ﬁve years to fund the very large epidemiological
study that might be needed to discover how the question
should be answered and how clinical guidance
12,13 operates
into clinical practice.
Reﬂections
Many questions which are reasonable to ask – how quickly
pharmaceutical drugs take effect, what adverse effects arise
from those drugs, whether a baby has been intentionally
injured by a guardian – are very difﬁcult to answer reliably.
For common acute conditions, results might accumulate
quite quickly. For chronic diseases, such as diabetes or epi-
lepsy, where adverse effects might develop only after longer
term use of a drug, there are no rapid ways of discovering
deleterious effects.
If the incidence of death or an adverse effect is
common, then relatively few patients need be studied. The
NHS’s deﬁnition of ‘common’ is ‘one in 10 to one in 100’.
Reliably to detect a difference between an adverse event
rate of one in 10 per month versus one in 20 per month
would require recruiting 870 patients and observing them
accurately for a month (5% signiﬁcance, 80% power). To be
95% to 99% conﬁdent of ruling out an adverse event rate
of one in 1000 (or one in 10,000), some 3000 to 5000 (or
30,000 to 50,000) patients would have to be studied
without observing a single event.
4
There might not be as many patients as are needed to
answer a question such as: ‘does controlling type 1 diabetes
by insulin pump rather than by injections lead to healthier
newborns?’ This clearly needs a study of diabetic women
who are planning to have children, or have had children. As
there are only about 280,000 people in the UK of both sexes
and all ages who have type 1 diabetes, the number of UK
women who might be included in such a study is not large.
A response to the difﬁculty of obtaining good-quality
scientiﬁc evidence on risks might be to seek clinical
opinion. A clinical opinion can only summarize the scienti-
ﬁc rationale (as currently known), personal experience, and
published research. Personal experience of rare events is
logically limited.
In assessing risks, and answering questions, prudence is
recommended. No matter how much we may want an
answer, or how tragic the individual outcome, we can only
work from the available evidence or on improving the
evidence base cost-efﬁciently.
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